Louisiana sends Takeda $9-billion Actos bill

Share this article:

A Louisiana court slapped Takeda and partner Lilly with punitive damages of $9 billion over the diabetes drug Actos. The split is $6 billion Takeda, $3 billion for co-promoter Lilly, but Lilly noted in a statement that its agreement with Takeda indemnifies the company from litigation losses and expenses.

The lawsuit is one of several against the drugmakers over allegations that they tried to hide the cancer risk associated with the medication.

Lilly Senior Vice Chairman and General Counsel Mike Harrington said in a statement that the firm will “vigorously challenge this outcome through all available legal means.”

Litigation results have been elastic—Bloomberg notes that although California and Maryland juries hit Takeda with $8.2 million in damages over Actos, “judges in both states threw out the verdicts.”

Reuters notes that the $9 billion in damages surpass the $5 billion leveled at Exxon over the 1989 Exxon Valdez oil spill and that these damages are “meant to discourage other companies from bad conduct.” Reuters also notes that Germany and France banned the drug three years ago “due to worries about a possible link to cancer.”

The Associated Press reports that a 2011 FDA drug safety update said Actos was associated with a 40% increase in bladder cancer among Actos patients who used the drug for more than a year.

The Louisiana court also awarded $1.5 million for patient compensation.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

AbbVie nabs Shire for $54B

AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.